Population pharmacokinetics of everolimus in de novo renal transplant patients: Impact of ethnicity and comedications

被引:96
作者
Kovarik, JM [1 ]
Hsu, CH [1 ]
McMahon, L [1 ]
Berthier, S [1 ]
Rordorf, C [1 ]
机构
[1] Novartis Pharma AG, CH-4002 Basel, Switzerland
关键词
D O I
10.1067/mcp.2001.118022
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background. Everolimus is a macrolide immunosuppressant intended for acute rejection prophylaxis after kidney transplantation. Methods: A total of 5260 blood samples were collected in the context of two randomized, double-blind, multicenter efficacy trials in 673 patients over a 6-month period after kidney transplantation. The data were evaluated in a nonlinear mixed-effects model. The influence of demographic characteristics (age, weight, sex, and ethnicity) and of comedications on everolimus exposure was explored. Results: For a reference 44-year-old, 71-kg Caucasian kidney allograft recipient receiving everolimus as part of a cyclosporine (INN, ciclosporin)-prednisone immunosuppressive regimen, the absorption rate constant was 6.07 h(-1) (standard error [SE], 0.70 h(-1)), the apparent clearance was 8.8 L/h (SE, 0.2 L/h), and the apparent central distribution volume was 110 L (SE, 5 L). There were no clinically relevant influences of age, weight, or sex on clearance. No significant difference in clearance was detected for Asian patients, whereas black patients had an average clearance that was 20% higher than that of nonblack patients. Patients concomitantly receiving erythromycin or azithromycin had an average 19% lower clearance. One patient receiving itraconazole had a 74% reduction in clearance. After we accounted for covariates, the remaining interindividual variability in clearance was 27% and the variability for distribution volume was 36%. The combined intraindividual and assay/measurement residual error, in everolimus blood concentrations was 31%. Conclusions: Dose adjustment of everolimus on the basis of weight does not appear necessary. Black patients may need a higher dose to achieve exposure that is similar to that of nonblack patients. Concomitant administration of potent inhibitors of the cytochrome P450 isozyme CYP3A may reduce everolimus clearance and increase its blood concentrations.
引用
收藏
页码:247 / 254
页数:8
相关论文
共 15 条
  • [1] BEAL SL, 1992, NONMEM USERS GUIDE
  • [2] Clinically significant drug interactions with cyclosporin - An update
    Campana, C
    Regazzi, MB
    Buggia, I
    Molinaro, M
    [J]. CLINICAL PHARMACOKINETICS, 1996, 30 (02) : 141 - 179
  • [3] In vitro biotransformation of SDZ RAD: A new immunosuppressive macrolide in human liver microsomal preparations
    Dannecker, R
    Vickers, AEM
    Ubeaud, G
    Hauck, C
    [J]. TRANSPLANTATION PROCEEDINGS, 1998, 30 (05) : 2206 - 2206
  • [4] Steady-state pharmacokinetics and tolerability of RAD and its influence on cyclosporine in stable renal transplant patients
    Dantal, J
    Lehne, G
    Winkler, M
    Hauser, IA
    Lison, AE
    Soulillou, JP
    Budde, K
    Fauchald, P
    Müller, L
    Paradis, K
    Kovarik, JM
    Neumayer, HH
    [J]. TRANSPLANTATION, 1999, 67 (07) : S160 - S160
  • [5] KATZNELSON S, 1995, CLIN TRANSPL, V9, P379
  • [6] Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: Pharmacokinetics, exposure-response relationships, and influence on cyclosporine
    Kovarik, JM
    Kahan, BD
    Kaplan, B
    Lorber, M
    Winkler, M
    Rouilly, M
    Gerbeau, C
    Cambon, N
    Boger, R
    Rordorf, C
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (01) : 48 - 56
  • [7] The pharmacokinetics and metabolic disposition of tacrolimus: A comparison across ethnic groups
    Mancinelli, LM
    Frassetto, L
    Floren, LC
    Dressler, D
    Carrier, S
    Bekersky, I
    Benet, LZ
    Christians, U
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (01) : 24 - 31
  • [8] Gender-dependent racial difference in disposition of cyclosporine among healthy African American and white volunteers
    Min, DI
    Lee, M
    Ru, YM
    Flanigan, M
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 68 (05) : 478 - 486
  • [9] The side effect profile of sirolimus: A phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients
    Murgia, MG
    Jordan, S
    Kahan, BD
    [J]. KIDNEY INTERNATIONAL, 1996, 49 (01) : 209 - 216
  • [10] Neumayer HH, 1999, BRIT J CLIN PHARMACO, V48, P694